08:12 AM EDT, 08/19/2024 (MT Newswires) -- Scisparc ( SPRC ) shares rose more than 21% in premarket activity on Monday after it signed an exclusive patent license agreement with Polyrizon for its SCI-160 pain treatment program.

Under the agreement, Polyrizon would receive exclusive, royalty-bearing global license to develop and sublicense the assets.

The company said it would receive $3 million in Polyrizon securities, about $3 million in potential milestone fees if certain development milestones are met, and royalties.

Price: 0.4258, Change: +0.06, Percent Change: +15.08